Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Upa30-LP
2025-522870-35-00Phase 2Authorised
- Sponsor
- Centre Hospitalier Universitaire de Nice
- Start
- Nov 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in lichen planus (LP) and lichen planopilaris (LPP) comparing Upadacitinib 30 mg with Placebo (2 arms). Primary endpoint: Achievement of IGA response (absolute IGA score ≤2) at Week 16. Planned start Nov 2026; status: authorised.
02
Drugs
upadacitinib
03
Conditions
lichen planus (LP)lichen planopilaris (LPP)
Beyond the preview
Go deeper on 2025-522870-35-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522870-35-00.